NCT03098862View on ClinicalTrials.gov

PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response

CompletedOBSERVATIONAL
Enrollment

4,830

Participants

Timeline

Start Date

September 4, 2017

Primary Completion Date

February 28, 2019

Study Completion Date

December 23, 2020

Conditions
Ebola Virus Disease
Trial Locations (4)

Unknown

PREVAIL C. H. Rennie Hospital, Kalkata

PREVAIL JFK Medical Center, Monrovia

PREVAIL Redemption Hospital, Monrovia

PREVAIL Duport Road Clinic, Paynesville

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03098862 - PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response | Biotech Hunter | Biotech Hunter